FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Hall Justin
2. Issuer Name and Ticker or Trading Symbol

NovaBay Pharmaceuticals, Inc. [ NBY ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Interim President & CEO and GC
(Last)          (First)          (Middle)

C/O NOVABAY PHARMACEUTICALS, INC., 2000 POWELL STREET, SUITE 1150
3. Date of Earliest Transaction (MM/DD/YYYY)

6/10/2019
(Street)

EMERYVILLE, CA 94608
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

6/12/2019 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock (1) 6/10/2019    A    47500  A $2.02  50905  D   
Common Stock (1) 6/10/2019    S    47500  D $3.03  3405  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)  $2.02  6/10/2019    X        47500   5/31/2019  5/31/2028  Common Stock  47500  $0  0  D   

Explanation of Responses:
(1)  The amended Form 4 is being filed to show (1) the corresponding acquisition of common stock after the exercise of options in Table I and (2) the immediate sale of common stock after such exercise of options in Table I.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Hall Justin
C/O NOVABAY PHARMACEUTICALS, INC.
2000 POWELL STREET, SUITE 1150
EMERYVILLE, CA 94608


Interim President & CEO and GC

Signatures
/s/ Justin Hall 10/28/2019
**Signature of Reporting Person Date


NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more NovaBay Pharmaceuticals Charts.
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more NovaBay Pharmaceuticals Charts.

Novabay Pharmaceuticals, Inc. News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
Friday 3 May 2024 (20 hours ago) • Business Wire
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
Monday 22 April 2024 (2 weeks ago) • Business Wire
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
Friday 19 April 2024 (2 weeks ago) • Business Wire
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
Wednesday 17 April 2024 (2 weeks ago) • Business Wire
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
Tuesday 26 March 2024 (1 month ago) • Business Wire
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
Monday 25 March 2024 (1 month ago) • Business Wire
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
Thursday 14 March 2024 (2 months ago) • Business Wire
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Wednesday 14 February 2024 (3 months ago) • Edgar (US Regulatory)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Tuesday 6 February 2024 (3 months ago) • Edgar (US Regulatory)
NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales
Tuesday 30 January 2024 (3 months ago) • Business Wire
Form 8-K - Current report
Wednesday 10 January 2024 (4 months ago) • Edgar (US Regulatory)
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
Tuesday 9 January 2024 (4 months ago) • Business Wire